Core Viewpoint - The company, Kaisheng Securities, has faced significant challenges in its IPO process, including the withdrawal of its application and ongoing internal control issues, which have adversely affected its business operations and financial performance [2][3][11]. Group 1: IPO Process and Regulatory Issues - Kaisheng Securities' IPO application was submitted in July 2022, but the review process has been stalled for approximately three years, with no substantial progress since the initial inquiry in April 2023 [2][4]. - The withdrawal of the IPO application is linked to the change of accounting firms, as state-owned enterprises are limited to hiring the same firm for a maximum of eight years [2][4]. - The company may consider reapplying for the IPO in 2026, indicating a potential delay in its public offering plans [2]. Group 2: Financial Performance - In 2024, Kaisheng Securities reported revenues of 28.59 billion yuan, a decrease of 6.61% year-on-year, while net profit increased by 12.78% to 6.95 billion yuan, indicating profit growth despite declining revenues [4][5]. - The company's revenue from various segments showed mixed results, with a significant drop in commission income and net interest income, while investment income surged by 146% [5][6]. - The company heavily relies on the Shaanxi market, with 101.62% of its revenue and 155.8% of its operating profit coming from this region in 2024 [6][8]. Group 3: Business Operations and Internal Control - Kaisheng Securities has faced operational challenges due to internal control issues, leading to a six-month suspension of its bond underwriting business [9][11]. - The company has been recognized for its strong performance in the New Third Board business, ranking first in several years, but its traditional IPO underwriting capabilities lag behind top competitors [10][11]. - The company has acknowledged its insufficient penetration in coastal economic regions and the need for a more rational network layout [7][8].

Industry Overview - The pharmaceutical industry is a strategic pillar for national health and economic development, increasingly gaining public and government attention [2][3] - The demand for healthcare is experiencing rigid growth due to economic development, improved living standards, and demographic changes [2] Company Performance - In Q1 2025, the company reported a revenue increase of 27.83% year-on-year, amounting to 27.22 million yuan, and a net profit increase of 197.23%, totaling 10.22 million yuan [3][12] - The growth is attributed to expanded sales channels and successful partnerships with major chain pharmacies [3][12] Product and Market Strategy - The company specializes in the research, production, and sales of traditional Chinese medicine (TCM), focusing on stable and effective formulations [3][5] - The company has over 70 approved products across various categories, including throat, cold, orthopedics, and gynecology [9][11] - The company is adapting to the normalized centralized procurement model, which has covered over 20 product groups and 95 varieties [3][5] Internal Control and Compliance - The company emphasizes internal control and compliance, enhancing management through dedicated personnel and electronic process controls [12] - Recent improvements include the establishment of a compliance culture and the introduction of a multi-tiered governance mechanism [12] Future Outlook - The company plans to leverage its "Guangdong Old Brand" title to enhance brand recognition and expand market share through strategic partnerships [12] - The focus will be on optimizing product structure and enhancing clinical and scientific value to improve market positioning [7][12] Financial Health - As of Q1 2025, the company reported total assets of 812.64 million yuan and a low debt-to-asset ratio of 10.89%, indicating strong liquidity [12]